You are here: Home: CACU 2 | 2006: Faculty Information
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and stateof-
the-art education. We assess potential conflicts of interest with faculty, planners and managers of
CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
validation process. The content of each activity is reviewed by both a member of the scientific staff
and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review
of content for educational activities and report the following real or apparent conflicts of interest for
themselves (or their spouses/partners) that have been resolved through a peer review process: Richard
Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD,
Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent
conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To
Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals
LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI
Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no
influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
of interest that have been resolved through a peer review process:
Dr Chlebowski — Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis
Pharmaceuticals, Pfizer Inc, Sanofi-Aventis; Grant Support: Amgen Inc. Dr Wolff — Contracted Research: Roche
Laboratories Inc. Dr Blum — Fees for Non-CME Services Received Directly from Commercial Interest or Their
Agents: Abraxis Oncology, Roche Laboratories Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
|
